I recently asked my husband, Jared, who has hemophilia, a this-or-that question: “Would you rather have many insignificant bleeds several times a month, or big bleeds several times a year that keep you bedridden for an entire month?” Jared chose the former, and I agreed. As a busy mom and entrepreneur,…

Treatment with Octapharma‘s Nuwiq is associated with a low risk of developing inhibitors — antibodies that prevent the medication from working properly — in previously untreated patients (PUPs) with hemophilia A, according to the results of a clinical trial. These findings were published in the journal Thrombosis…

A partnership between ARUP Laboratories and Medicover will improve access to AAV5 DetectCDx, the former’s companion diagnostic test to assess hemophilia A patients’ eligibility to Roctavian (valoctocogene roxaparvovec-rvox) in the European Union (EU). The partnership, which allows testing to be done at one of Medicover’s…

My last home had a great fence. It was a wall of concrete blocks surrounding my backyard and stood 7 feet high. With two dogs who bark at the wind blowing, the wall deterred them from jumping and kept some of their barking at bay. However, there was an iron…

A single infusion of valoctocogene roxaparvovec, BioMarin Pharmaceutical’s investigational gene therapy, can lead to the sustained production of factor VIII (FVIII) in people with hemophilia A, according to a biopsy study that showed the presence of the treatment’s gene constructs in the liver over nearly four…

Nuwiq (simoctocog alfa) effectively prevented and controlled bleeds in previously untreated people with severe hemophilia A, according to data from a Phase 3 clinical trial. Full trial results were reported in the study, “Simoctocog alfa (Nuwiq) in previously untreated patients with severe haemophilia A — Final efficacy…

BioMarin Pharmaceutical has resubmitted an application to the U.S. Food and Drug Administration (FDA) seeking approval of Roctavian (valoctocogene roxaparvovec), potentially the first gene therapy for adults with severe hemophilia A. The FDA delayed the company’s initial approval request in 2019, with the agency requiring two more…

I’ve found the stress of my first two months of fatherhood overwhelming. We’ve had many sleepless nights as we’ve adjusted to meeting the constant demands of a crying baby. My wife and I are incredibly sleep-deprived. But seeing my child smile when she sees my face first thing in the…

My condition, hemophilia, has always been an enigma for me. It’s been a huge challenge to my personal development, physical health, and mental stability. I wanted to believe that this disease was given to me for a reason. However, as the years progressed, I was wracked with hemophilia complications, and…

Once-daily preventive treatment with Novo Nordisk’s experimental therapy concizumab significantly reduced bleeding rates in people with both hemophilia A and B with inhibitors, according to new data from the Phase 3 explorer7 trial. In fact, bleeding rates in patients receiving concizumab in trial decreased by more than 85%. Based…